{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:55:42Z","timestamp":1790560542017,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"DOI":"10.1007\/s10620-026-10259-3","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:56:31Z","timestamp":1790513791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes During Concurrent Dupilumab and Advanced Immune-Modifying Therapy: A Real-World Cohort Study"],"prefix":"10.1007","author":[{"given":"Chethan","family":"Ramprasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna","family":"Wierzbicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa A.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Grossberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren G.","family":"Rabinowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"key":"10259_CR1","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","volume":"20","author":"W Ahmed","year":"2022","unstructured":"Ahmed W, Galati J, Kumar A et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20:e361\u2013e379. https:\/\/doi.org\/10.1016\/j.cgh.2021.03.034.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10259_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/ibd\/izaf188","volume":"32","author":"SR Anderson","year":"2026","unstructured":"Anderson SR, Osman A, Zamani M et al. Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel diseases. Inflamm Bowel Dis. 2026;32:39\u201352. https:\/\/doi.org\/10.1093\/ibd\/izaf188.","journal-title":"Inflamm Bowel Dis."},{"key":"10259_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103926","author":"AZ Lignou","year":"2025","unstructured":"Lignou AZ, Vassilakis KD, Baraliakos X et al. Combination targeted therapy with two biologic\/targeted synthetic DMARDs in 1200 patients with immune mediated inflammatory diseases: a systematic literature review for current landscape in safety and efficacy. Autoimmun Rev. 2025. https:\/\/doi.org\/10.1016\/j.autrev.2025.103926.","journal-title":"Autoimmun Rev."},{"key":"10259_CR4","doi-asserted-by":"publisher","first-page":"S935","DOI":"10.14309\/01.ajg.0001144944.27200.5a","volume":"120","author":"C Yuki","year":"2025","unstructured":"Yuki C, Wilder E, Mazer A, Konijeti G, Moawad FJ, Nhu Q. S4371 Concurrent use of dupilumab and other biologics in eosinophilic esophagitis (EoE) patients with concomitant immune-mediated conditions: a case series. Am J Gastroenterol. 2025;120:S935. https:\/\/doi.org\/10.14309\/01.ajg.0001144944.27200.5a.","journal-title":"Am J Gastroenterol."},{"key":"10259_CR5","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s10620-022-07684-5","volume":"68","author":"EA Spencer","year":"2023","unstructured":"Spencer EA, Dolinger MT, Dubinsky MC. A single-center experience with dupilumab for atopic or psoriasiform dermatitis in patients with inflammatory bowel disease. Dig Dis Sci. 2023;68:1936\u20131942. https:\/\/doi.org\/10.1007\/s10620-022-07684-5.","journal-title":"Dig Dis Sci."},{"key":"10259_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.02.023","author":"S Keow","year":"2025","unstructured":"Keow S, Lu B, Xiong G et al. Patient outcomes and safety of combination biologic therapy with dupilumab: a systematic review. Ann Allergy Asthma Immunol. 2025. https:\/\/doi.org\/10.1016\/j.anai.2025.02.023.","journal-title":"Ann Allergy Asthma Immunol."},{"key":"10259_CR7","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamadermatol.2025.2524","volume":"161","author":"A Wu","year":"2025","unstructured":"Wu A, Zhang A, Guo Y et al. Comparative risk of infection and prevalence of combination targeted therapy in psoriatic arthritis. JAMA Dermatol. 2025;161:1162\u20131166. https:\/\/doi.org\/10.1001\/jamadermatol.2025.2524.","journal-title":"JAMA Dermatol."},{"key":"10259_CR8","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00403-022-02435-5","volume":"315","author":"D Lukac","year":"2023","unstructured":"Lukac D, Pagani K, McGee JS. Overview of use, efficacy, and safety of dupilumab in complex patients: a retrospective, case-series study from a large, urban academic center. Arch Dermatol Res. 2023;315:1637\u20131644. https:\/\/doi.org\/10.1007\/s00403-022-02435-5.","journal-title":"Arch Dermatol Res."},{"key":"10259_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2147\/JAA.S507008","volume":"18","author":"Y Chen","year":"2025","unstructured":"Chen Y, Wang L, Xie J. Combining dual biologics therapy for severe asthma: a series of ten cases. J Asthma Allergy. 2025;18:507\u2013517. https:\/\/doi.org\/10.2147\/JAA.S507008.","journal-title":"J Asthma Allergy."},{"key":"10259_CR10","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00403-025-04196-w","volume":"317","author":"IC Silva","year":"2025","unstructured":"Silva IC, Daher R, Khattri S. Combined use of omalizumab and dupilumab: safety and efficacy data from a large academic center. Arch Dermatol Res. 2025;317:674. https:\/\/doi.org\/10.1007\/s00403-025-04196-w.","journal-title":"Arch Dermatol Res."},{"key":"10259_CR11","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/ueg2.12170","volume":"9","author":"L Goessens","year":"2021","unstructured":"Goessens L, Colombel J, Outtier A et al. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: a European retrospective observational study. United Eur Gastroenterol J. 2021;9:1136\u20131147. https:\/\/doi.org\/10.1002\/ueg2.12170.","journal-title":"United Eur Gastroenterol J."},{"key":"10259_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/apt.15719","volume":"51","author":"E Yang","year":"2020","unstructured":"Yang E, Panaccione N, Whitmire N et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn\u2019s disease. Aliment Pharmacol Ther. 2020;51:1031\u20131038. https:\/\/doi.org\/10.1111\/apt.15719.","journal-title":"Aliment Pharmacol Ther."},{"key":"10259_CR13","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1007\/s10620-024-08379-9","volume":"69","author":"A Kellar","year":"2024","unstructured":"Kellar A, Dolinger MT, Spencer EA, Dubinsky MC. Real-world outcomes of dual advanced therapy in children and young adults with inflammatory bowel disease. Dig Dis Sci. 2024;69:1826\u20131833. https:\/\/doi.org\/10.1007\/s10620-024-08379-9.","journal-title":"Dig Dis Sci."},{"key":"10259_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/biom15020222","volume":"15","author":"G Altieri","year":"2025","unstructured":"Altieri G, Zilli A, Parigi TL et al. Dual therapy in inflammatory bowel disease. Biomolecules. 2025;15:222. https:\/\/doi.org\/10.3390\/biom15020222.","journal-title":"Biomolecules."},{"key":"10259_CR15","first-page":"251","volume":"19","author":"V Solitano","year":"2023","unstructured":"Solitano V, Ma C, Han\u017eel J et al. Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease. Gastroenterol Hepatol. 2023;19:251\u2013263.","journal-title":"Gastroenterol Hepatol."},{"key":"10259_CR16","first-page":"406","volume":"17","author":"SL Gold","year":"2021","unstructured":"Gold SL, Steinlauf AF. Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature. Gastroenterol Hepatol. 2021;17:406\u2013414.","journal-title":"Gastroenterol Hepatol."},{"key":"10259_CR17","doi-asserted-by":"publisher","first-page":"otac002","DOI":"10.1093\/crocol\/otac002","volume":"4","author":"QA Alayo","year":"2022","unstructured":"Alayo QA, Fenster M, Altayar O et al. Systematic review with meta-analysis: safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease. Crohns Colitis 360. 2022;4:otac002. https:\/\/doi.org\/10.1093\/crocol\/otac002.","journal-title":"Crohns Colitis 360."},{"key":"10259_CR18","doi-asserted-by":"publisher","first-page":"175628482413098","DOI":"10.1177\/17562848241309871","volume":"18","author":"A Fabisiak","year":"2025","unstructured":"Fabisiak A, Caban M, Dudek P, Strig\u00e1\u010d A, Ma\u0142ecka-Wojciesko E, Talar-Wojnarowska R. Advancements in dual biologic therapy for inflammatory bowel diseases: efficacy, safety, and future directions. Therap Adv Gastroenterol. 2025;18:17562848241309872. https:\/\/doi.org\/10.1177\/17562848241309871.","journal-title":"Therap Adv Gastroenterol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10259-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-10259-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-10259-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:02:00Z","timestamp":1790557320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-10259-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":18,"alternative-id":["10259"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-10259-3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"28 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}